A study found an artery-sealing device stopped bleeding in under a minute on average. FDA approved it.
Haemonetics' PerQseal Elite system, a sutureless vascular closure device, received FDA approval. The device stops bleeding in under a minute on average and is bioabsorbable. According to the company, it simplifies procedures like TAVR and improves patient comfort. Haemonetics plans to present clinical data at the TCT Conference in October.
How this was made
The 30-second read
Why it matters
The FDA clearance adds a new revenue stream and could improve the company's growth outlook.
Market read
First‑time FDA approval for a novel vascular closure device; likely positive catalyst for HAE stock.
What to watch
Reimbursement rates and competition from established closure devices could temper upside.
Background
Haemonetics is a global medical‑technology company with businesses in apheresis, blood management, and interventional technologies.
Ticker impact
Haemonetics received FDA approval for its PerQseal Elite vascular closure system, a new product launch.
likely upward pressure as investors price in new product revenue potential
First disclosure of FDA clearance; market typically reacts positively to new medical device approvals.
Market effects
May lift other vascular closure and interventional device makers as the market sees expanded adoption.
U.S. medical device sector could see modest gains.
Limited to U.S. listed med‑tech stocks; no broad macro effect.
Counterpoint
If adoption is slower than expected, the approval may not translate into near‑term revenue.
Key entities
- CompanyHaemonetics Corp
US‑listed medical‑technology firm (NASDAQ: HAE).
- ExecutiveJan Hartmann, M.D.
Senior Vice President and Chief Medical Officer at Haemonetics.
